MRI Evaluation of Chest Pain Compatible With Myocardial Ischemia
MRI
Arterial Occlusive Diseases+15
+ Arteriosclerosis
+ Cardiovascular Diseases
Treatment Study
Summary
Study start date: December 1, 1999
Actual date on which the first participant was enrolled.Coronary artery disease remains the leading cause of death in the United States and results in high diagnostic and therapeutic costs. The overall costs associated with the care of patients with cardiovascular disease is projected to be $286.5 billion. Although MRI is a relatively expensive technology, this methodology can provide all the noninvasive diagnostic testing necessary to evaluate and triage patients with coronary artery disease. This "one stop shop" has the potential to lower overall testing on this important patient population and better delineate which patients require intervention. Beyond reproducing the results of existing diagnostic tests, MRI has unique abilities to characterize myocardial tissue adding information in the assessment of these patients that is not attainable by currently available methodologies. This study will examine the hypothesis that MRI assessment of regional LV function, resting myocardial perfusion, and myocardial tissue characteristics can accurately detect a higher fraction of patients with acute myocardial infarction than is possible with the ECG performed in the emergency department.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.360 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
INCLUSION CRITERIA: Ages above age 21 (children are excluded because myocardial infarction is so rare in this population that the pre-test probability is comparable to the patients with less than 30 minutes of symptoms. Both of these groups have too small a fraction of true positive events to benefit from testing with a sensitivity and specificity of approximately 0.85. If initial results are better, we will reexamine the suitability of these tests for low risk populations). Capable of giving informed consent. 30 minutes of chest pain compatible with myocardial ischemia (chest pain score greater than 4). Less than 270 pounds. EXCLUSION CRITERIA: Medical exclusions: Patient states she may be pregnant (confirmed by urine or blood testing). Severe congestive heart failure (unable to lie flat in bed). Subjects on a mechanical ventilator. MRI exclusions: Subjects with a cardiac pacemaker or implantable defibrillator. Subjects with a cerebral aneurysm clip. Subjects with a neural stimulator (e.g. TENS-Unit). Subjects with any type of ear implant. Subjects with metal in eye (e.g. from machining). Subjects with implanted devices (e.g. insulin pump, drug infusion device).
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, United StatesOpen National Heart, Lung and Blood Institute (NHLBI) in Google Maps